Endocrine Abstracts

Temozolomide (TMZ) is an oral chemotherapy first used for pituitary tumours in 2006. Over the past 12 years experience and confidence using this treatment has increased. Temozolomide is effective: with about 50% of cases showing a tumour response. This figure rises to 70% if stable disease is regarded as a tumour response. The effectiveness appears to be similar in both aggressive adenoma and carcinoma. Functioning tumours show a better response as compared with non-functionin...

The clinical course of pituitary adenoma is highly variable. Aggressive adenoma subtypes may require multimodal therapy with multiple operations. Even standard adenoma exhibit a relatively high long term recurrence rate and delayed intervention is often required. The indications for revision surgery in the endoscopic era are expanding for both functioning and non-functioning tumours, including access to the medial and lateral cavernous sinus and intracranial compartments. Alth...

This talk aims to explain:• What is proton beam therapy (PBT)• How it is delivered• Clinical indications for PBT• Evidence for its use• Challenges• UK service – current and future...